The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide
range of incurable diseases. Recent rapid advances in biotechnology and molecular …

The past several months have witnessed the emergence of SARS-CoV-2 variants with novel
spike protein mutations that are influencing the epidemiological and clinical aspects of the …

Where 2020 saw the development and testing of vaccines against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented pace, the first half of 2021 has …

The germinal centre (GC) response is critical for the generation of affinity-matured plasma
cells and memory B cells capable of mediating long-term protective immunity …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus
disease 2019 (COVID-19), emerged in China in December 2019 and quickly spread around …

Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of
concern pose a challenge to the effectiveness of current vaccines. A vaccine that could …

Background COVID-19 vaccine supply shortages are causing concerns about compromised
immunity in some countries as the interval between the first and second dose becomes …

Compared with traditional drug therapy, nanomedicines exhibit intriguing biological features
to increase therapeutic efficiency, reduce toxicity and achieve targeting delivery. This review …

The COVID-19 pandemic has profound adverse effects on the population on dialysis.
Patients requiring dialysis are at an increased risk of SARS-CoV-2 infection and mortality …

COVID-19 vaccine design and vaccination rollout need to take into account a detailed
understanding of antibody durability and cross-neutralizing potential against SARS-CoV-2 …